Promoted Content
Promoted Content

Find Clinical Drug Pipeline Developments & Deals by Lonza Group

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): Allogeneic cardiosphere-derived cells

            Therapeutic Area: Genetic Disease Product Name: CAP-1002

            Highest Development Status: Phase II Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Capricor Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 12, 2021

            Details:

            Capricor to leverage Lonza’s expertise in technology transfer and development of cellular therapies to take CAP-1002 through potential product launch and commercial supply.

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): Voclosporin

            Therapeutic Area: Immunology Product Name: ISA247

            Highest Development Status: Phase III Product Type: Peptide

            Partner/Sponsor/Collaborator: Aurinia Pharmaceuticals

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration December 15, 2020

            Details:

            The dedicated facility will be equipped with state-of-the-art manufacturing equipment to provide cost and production efficiency for the manufacture of voclosporin, while expanding existing capacity and providing supply security to meet future commercial demand.

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): AdCOVID

            Therapeutic Area: Infections and Infectious Diseases Product Name: AdCOVID

            Highest Development Status: Preclinical Product Type: Vaccine

            Partner/Sponsor/Collaborator: Altimmune

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership November 10, 2020

            Details:

            Altimmune's agreement with Lonza expands its current clinical and commercial manufacturing strategy for AdCOVID. AdCOVID, a single-dose intranasal vaccine for COVID-19, designed to generate a broad immune response with the unique ability to promote nasal mucosal immunity.

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): AZD7442

            Therapeutic Area: Infections and Infectious Diseases Product Name: AZD7442

            Highest Development Status: Phase I Product Type: Large molecule

            Partner/Sponsor/Collaborator: AstraZeneca PLC

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement October 30, 2020

            Details:

            Lonza will manufacture drug substance (DS) for AZD7442 at Lonza's facilities in Portsmouth (US). Operations are expected to start in H1 2021. AstraZeneca will be one of the first companies to access Lonza's new mid-scale facilities in Portsmouth, NH (USA).

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): NILK-2301

            Therapeutic Area: Oncology Product Name: NILK-2301

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: LamKap Bio Group

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 18, 2020

            Details:

            Lonza will provide cell line and process development, drug substance manufacturing and drug product services of LamKap's two fully human bispecific antibody products, NILK-2301 and NILK-2401.

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): Lenzilumab

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Humanigen

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration September 15, 2020

            Details:

            Collaboration to expand lenzilumab manufacturing capacity in advance of potential Emergency Use Authorization in 2020.

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): KSI-301

            Therapeutic Area: Ophthalmology Product Name: KSI-301

            Highest Development Status: Phase II/ Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Kodiak Sciences

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement July 27, 2020

            Details:

            Purpose-built bioconjugation facility in Lonza’s Ibex™ Dedicate Biopark to support the potential commercial launch of Kodiak's leading ophthalmic therapeutic candidate KSI-301 with a capacity to supply millions of doses per year.

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): Abelacimab

            Therapeutic Area: Hematology Product Name: Undisclosed

            Highest Development Status: Undisclosed Product Type: Large molecule

            Partner/Sponsor/Collaborator: Anthos Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership June 11, 2020

            Details:

            The agreement furthers Anthos Therapeutics mission to develop Abelacimab for patients at risk of thrombotic events, which are currently underserved by conventional anti-coagulant therapies.

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): Wnt Activating Antibodies

            Therapeutic Area: Trauma (Emergency, Injury, Surgery) Product Name: Undisclosed

            Highest Development Status: Preclinical Product Type: Large molecule

            Partner/Sponsor/Collaborator: Surrozen

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 29, 2020

            Details:

            Lonza to provide cell line development, drug substance and drug product process development and cGMP manufacturing, and regulatory support for IND filing. Lonza’s Light Path™ cell line development program will be tailored enabling Surrozen to prepare for their IND filing.

            Virtual BoothGlobal Pharmaceutical Dosage Solutions Company

            Contact the Supplier

            Lead Product(s): mRNA-1273

            Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Vaccine

            Partner/Sponsor/Collaborator: Moderna Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration May 01, 2020

            Details:

            Moderna plans to establish manufacturing suites at Lonza’s facilities in the United States and Switzerland for the manufacture of mRNA-1273 at both sites.